Tumor necrosis factor-mediated disposition of infliximab in ulcerative colitis patients

Dynamics of circulating TNF during adalimumab treatment using a drug-tolerant TNF assay

(2019) Lea C. Berkhout et al.   Science Translational Medicine

Pharmacokinetic and pharmacodynamic model for analysis of adalimumab administered for Crohn's disease

(2018) Koji Kimura et al.   BIOPHARMACEUTICS & DRUG DISPOSITION

Synergistic Cytokine Effects as Apremilast Response Predictors in Patients With Psoriasis

(2018) Sandra Garcet et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Pharmacokinetic Features and Presence of Antidrug Antibodies Associate With Response to Infliximab Induction Therapy in Patients With Moderate to Severe Ulcerative Colitis

(2016) Johannan F. Brandse et al.   Clinical Gastroenterology and Hepatology

Evaluation of highly sensitive immunoassay technologies for quantitative measurements of sub-pg/mL levels of cytokines in human serum

(2016) David Yeung et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Therapeutic TNF Inhibitors can Differentially Stabilize Trimeric TNF by Inhibiting Monomer Exchange

(2016) Karin A. van Schie et al.   Scientific Reports

Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice

(2015) D. J. Buurman et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease

(2014) Iris Dotan et al.   INFLAMMATORY BOWEL DISEASES

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

(2013) Niels Vande Casteele et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum

(2012) Shui-Long Wang et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Ulcerative colitis

(2012) Ingrid Ordás et al.   LANCET

Single molecule measurements of tumor necrosis factor α and interleukin-6 in the plasma of patients with Crohn's disease

(2011) Linan Song et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Theory-based analysis of anti-inflammatory effect of infliximab on Crohn’s disease and rheumatoid arthritis

(2010) Koji Kimura et al.   RHEUMATOLOGY INTERNATIONAL

Identification of Key Processes that Control Tumor Necrosis Factor Availability in a Tuberculosis Granuloma

(2010) Mohammad Fallahi-Sichani et al.   PLoS Computational Biology

Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor

(2009) Zehra Kaymakcalan et al.   CLINICAL IMMUNOLOGY

Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis

(2009) Adedigbo A. Fasanmade et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Approximations of the target-mediated drug disposition model and identifiability of model parameters

(2008) Leonid Gibiansky et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS